Navigation Links
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Date:5/7/2008

Munich and Freiburg, Germany, May 7, 2008 / b3c newswire / – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.

Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, optimized and quality-controlled for successful crystallization. In addition, the two companies will work closely together to provide new crystal-grade protein or crystal structures, tailored to meet customers’ needs.

Recombinant protein kinases, optimized for crystallization, will be produced and exclusively marketed by ProQinase, while CRELUX will continue to provide customers with crystallization and x-ray crystallography services. CRELUX will support ProQinase by performing crystallization quality control for each crystal grade protein batch. At the same time, ProQinase will grant CRELUX privileged direct access to kinase crystal-grade protein.

“This new joint crystal-grade kinase platform offers tremendous advantages: It enables us to continue to focus on our core expertise – complex structure solution – while leveraging the expertise of ProQinase to significantly strengthen our capacities in protein expression,” commented Dr. Michael Schäffer, CEO of CRELUX.

“The combination of CRELUX’s expertise in protein crystallography and ProQinase’s know-how in kinase cloning and expression makes the two companies the partners of choice for all customers interested in kinase crystallography,” noted Dr. Christoph Schächtele, CEO of ProQinase.

CRELUX has used its state-of-the-art structural biology platform to solve more than 250 crystal and co-crystal structures for pharma and biotech companies. This platform encompasses all steps – from target cloning and exgy" timex="5/7/2008 6:21:44 PM" dirsub="(pression all the way to high-throughput ...)" id="5204" index="biology" dir="CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform" dir2="CRELUX and ProQinase establish joint crystal-grade kinase protein and structure..." keywords1=",biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology" keywords="CRELUX,and,ProQinase,establish,joint,crystal-grade,kinase,protein,and,structures,platform" description="pression all the way to high-throughput protein crystallization and in...ProQinase as part of its integrated protein kinase technology platfor... Download Pictures (high resolution):   Cli... For further information please contact: ... Notes to editors ..." url=u&"/biology-technology-1/CRELUX-and-ProQinase-establish-joint-crystal-grade-kinase-protein-and-structures-platform-5204-2/" title="CRELUX%20and%20ProQinase%20establish%20joint%20crystal-grade%20kinase%20protein%20and%20structures%20platform" %> CRELUX and ProQinase establish joint crystal-grade kinase protein and structure... ( Munich and Freiburg Germany May 7 200...)

CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Date:5/7/2008

pression all the way to high-throughput protein crystallization and in-house x-ray crystallography.

ProQinase, as part of its integrated protein kinase technology platform, offers more than 150 recombinant human protein kinases – all produced in-house – and provides all types of in vitro testing services, with more than 220 protein kinases.

Download Pictures (high resolution): 
Click on the picture with the right mouse button then choose "save target as".


Caption:
Protein crystals grown with crystal-grade kinases.


For further information please contact:
Dr. Michael Schäffer – CEO CRELUX GmbH – Tel: +49-89-700760-170
Dr. Alexander Baumann – ProQinase GmbH – Tel.: +49-761-206-1780  


Notes to editors

CRELUX GmbH gy" timex="5/7/2008 6:21:44 PM" dirsub="(ttp://www.crelux.com/ www.crelux.com ) p...)" id="5204" index="biology" dir="CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform" dir2="CRELUX and ProQinase establish joint crystal-grade kinase protein and structure..." keywords1=",biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology" keywords="CRELUX,and,ProQinase,establish,joint,crystal-grade,kinase,protein,and,structures,platform" description="ttp://www.crelux.com/ www.crelux.com ) provides fast and affordabl...ProQinase GmbH ( www.proqinase.com..." url=u&"/biology-technology-1/CRELUX-and-ProQinase-establish-joint-crystal-grade-kinase-protein-and-structures-platform-5204-3/" title="CRELUX%20and%20ProQinase%20establish%20joint%20crystal-grade%20kinase%20protein%20and%20structures%20platform" %> CRELUX and ProQinase establish joint crystal-grade kinase protein and structure... ( Munich and Freiburg Germany May 7 200...)

CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Date:5/7/2008

(www.crelux.com) provides fast and affordable access to co-crystal structures for biotech and pharma companies worldwide. Three dimensional structures of target-compound complexes are unique sources of information during the rational drug discovery process. Straightforward availability of structural data at an early stage of the drug development process significantly enhances productivity and success rates during hit selection, lead generation, and lead optimization. CRELUX has streamlined the processes of structure generation and solved hundreds of co-crystal structures using an integrated technology platform. In addition to customer designed projects crystallization conditions of numerous relevant therapeutic targets are available within the Off-The-Shelf Program of CRELUX. Off-The-Shelf target structures are delivered at a fixed price and short turn around times, facilitating affordable access to structural information.

ProQinase GmbH (www.proqinase.com) provides an Integrated Protein Kinase Technology (iProKiTe®) Platform for preclinical drug development of protein kinase inhibitors. More than 150 highly active recombinant kinases are offered for sale and more than 220 kinases are available for in vitro testing services (HTS and selectivity profiling etc.). Cellular and in vivo test systems including orthotopic tumor models allow further testing of lead compounds. A Clinical biomarker analysis service supports the evaluation of clinical trials.
'/>"/>

b3c newswire

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
3. European Centre for Modern Drug Discovery Established in Hamburg
4. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. KGI and Smith College Establish Leadership Forum for Women in Bioscience
7. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
8. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
9. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
10. Inverness - Chemogen Establish Exclusive License for TB Antibodies
11. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):